Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SATELITE salvage therapy trial in granulomatosis with polyangiitis
2021-000679-35Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of rituximab, tocilizumab and abatacept in granulomatosis with polyangiitis (GPA) (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Response or remission at 12 weeks. Started Jun 2021; status: active.
02
Drugs
rituximabtocilizumababatacept
03
Conditions
granulomatosis with polyangiitis (GPA)
Beyond the preview
Go deeper on 2021-000679-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000679-35.